Active surveillance for early-stage prostate cancer : Review of the current literature (pages 1650–1659)
Marc A. Dall'Era, Matthew R. Cooperberg, June M. Chan, Benjamin J. Davies, Peter C. Albertsen, Laurence H. Klotz, Christopher A. Warlick, Lars Holmberg, Donald E. Bailey Jr, Meredith E. Wallace, Philip W. Kantoff and Peter R. Carroll
Version of Record online: 27 FEB 2008 | DOI: 10.1002/cncr.23373
Active surveillance with delayed intervention appears to be a viable option for carefully selected men with low-risk prostate cancer. Although a significant number of men may ultimately require other forms of therapy, active surveillance offers the opportunity to delay active treatment and its associated morbidities until evidence of clinical progression is found. In the absence of long-term data, results from current studies must be interpreted with caution and any men electing surveillance must be monitored carefully and frequently.